Related KOL Coal Companies Lobby For Clean Energy Subsidies Silver Shines Among 2016's Best ETFs
The VanEck Vectors Coal ETF (NYSE: KOL) was one of last year's best-performing non-leveraged exchange-traded funds for a simple reason: Of the two nominees for the U.S. presidency, one was vocal in her disdain for the coal industry while one vowed to restore the industry's lost jobs.
President Donald Trump, obviously, was the candidate that promised to restore coal country's lost glory and KOL responded. The ETF is doing so again this year with a year-to-date gain of almost 18 percent. That means KOL has nearly doubled in value over the past year. Still, there are ample indications that Trump's promises to coal miners will be hard to keep.
Best Clean Energy Stocks To Watch Right Now: Novo Nordisk A/S(NVO)
- [By James E. Brumley]
When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.
In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.
While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.
As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’
- [By Logan Wallace]
Eagle Global Advisors LLC decreased its position in Novo Nordisk (NYSE:NVO) by 10.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,420 shares of the company’s stock after selling 15,550 shares during the period. Eagle Global Advisors LLC’s holdings in Novo Nordisk were worth $6,423,000 as of its most recent SEC filing.
- [By Paul Ausick]
Novo Nordisk A/S (NYSE: NVO) dropped about 1.5% on Friday to post a new 52-week low of $32.35 after closing at $32.84 on Thursday. The stock’s 52-week high is $59.00. Volume of about 3.4 million was close to the daily average of around 3.9 million shares. The drug maker had no specific news.
- [By Brian Orelli]
Novo Nordisk (NYSE:NVO) continues its trend ofrelatively strong growth of its newer diabetes medications being offset by slower growth of older insulin drugs in the first quarter. Currency changes also negatively affected Novo’s revenue line, but that’s out of the company’s control.
- [By Brian Orelli]
Global Blood Therapeutics (NASDAQ:GBT) is up 20% at 3:42 p.m. EST after Reuters reported that Novo Nordisk (NYSE:NVO) has approached the biotech about a potential acquisition.
Best Clean Energy Stocks To Watch Right Now: Adaptimmune Therapeutics plc(ADAP)
- [By Ethan Ryder]
Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.20, Bloomberg Earnings reports. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. During the same quarter in the prior year, the business earned ($3.00) EPS.
- [By Jon C. Ogg]
Adaptimmune Therapeutics PLC (NASDAQ: ADAP) was started with a Market Perform at Wells Fargo.
Aqua America Inc. (NYSE: WTR) was raised to Overweight from Equal Weight and the price target was raised to $36 from $33 (versus a $31.19 close) at Barclays.
Best Clean Energy Stocks To Watch Right Now: SITO Mobile, Ltd.(SITO)
- [By Stephan Byrd]
Birchview Capital LP lifted its position in shares of SITO Mobile (NASDAQ:SITO) by 16.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 140,000 shares of the Wireless communications provider’s stock after acquiring an additional 20,000 shares during the period. SITO Mobile accounts for 0.4% of Birchview Capital LP’s portfolio, making the stock its 25th biggest holding. Birchview Capital LP’s holdings in SITO Mobile were worth $563,000 at the end of the most recent reporting period.
Best Clean Energy Stocks To Watch Right Now: Corbus Pharmaceuticals Holdings, Inc.(CRBP)
- [By Sean Williams]
This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.
GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%
As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!
- [By Keith Speights]
Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.